"Receptors, Estrogen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.
Descriptor ID |
D011960
|
MeSH Number(s) |
D12.776.826.750.350 D12.776.930.778.350
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Estrogen".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Estrogen".
This graph shows the total number of publications written about "Receptors, Estrogen" by people in this website by year, and whether "Receptors, Estrogen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 14 | 9 | 23 |
1995 | 9 | 6 | 15 |
1996 | 4 | 7 | 11 |
1997 | 10 | 8 | 18 |
1998 | 10 | 12 | 22 |
1999 | 10 | 10 | 20 |
2000 | 20 | 13 | 33 |
2001 | 18 | 16 | 34 |
2002 | 11 | 15 | 26 |
2003 | 18 | 18 | 36 |
2004 | 15 | 20 | 35 |
2005 | 19 | 30 | 49 |
2006 | 14 | 24 | 38 |
2007 | 23 | 18 | 41 |
2008 | 11 | 19 | 30 |
2009 | 15 | 23 | 38 |
2010 | 26 | 25 | 51 |
2011 | 19 | 37 | 56 |
2012 | 24 | 38 | 62 |
2013 | 14 | 29 | 43 |
2014 | 14 | 29 | 43 |
2015 | 16 | 23 | 39 |
2016 | 9 | 16 | 25 |
2017 | 11 | 27 | 38 |
2018 | 8 | 22 | 30 |
2019 | 10 | 16 | 26 |
2020 | 8 | 18 | 26 |
2021 | 9 | 14 | 23 |
2022 | 3 | 17 | 20 |
2023 | 1 | 15 | 16 |
2024 | 9 | 11 | 20 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Estrogen" by people in Profiles.
-
A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study. Clin Cancer Res. 2024 Dec 02; 30(23):5304-5313.
-
Differential bone morphology and hypoxia activity in skeletal metastases of ER+ and ER- breast cancer. Commun Biol. 2024 Nov 21; 7(1):1545.
-
Nuclear staining for pan-Trk by immunohistochemistry is highly specific for secretory carcinoma of breast: pan-Trk in various subtypes of breast carcinoma. J Clin Pathol. 2024 Oct 20; 77(11):751-755.
-
Real-World Implications of the SOUND Trial. Ann Surg Oncol. 2024 Dec; 31(13):8776-8785.
-
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 01; 23(10):1494-1510.
-
Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer. JAMA Oncol. 2024 Oct 01; 10(10):1379-1389.
-
Estrogen signaling suppresses tumor-associated tissue eosinophilia to promote breast tumor growth. Sci Adv. 2024 Sep 27; 10(39):eadp2442.
-
A molecular switch from tumor suppressor to oncogene in ER+ve breast cancer: Role of androgen receptor, JAK-STAT, and lineage plasticity. Proc Natl Acad Sci U S A. 2024 Oct; 121(40):e2406837121.
-
The Estrogen Receptor-Related Orphan Receptors Regulate Autophagy through TFEB. Mol Pharmacol. 2024 Sep 17; 106(4):164-172.
-
Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial. Nat Med. 2024 Aug; 30(8):2242-2250.